Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines.
Vaccine
; 41(44): 6502-6513, 2023 Oct 20.
Article
in En
| MEDLINE
| ID: mdl-37620203
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Vaccine
Year:
2023
Document type:
Article
Affiliation country: